Myasthenia Gravis Global 7MM Market Forecast to Grow at 11.1% CAGR From $4.5 Billion in 2024 to $13.0 Billion in 2034 Per GlobalData
Analytics firm GlobalData published Wednesday September 2, 2026 a myasthenia gravis (MG) market forecast projecting the seven-major-markets (7MM: United States, France, Germany, Italy, Spain, United Kingdom, Japan) MG treatment market to grow from $4.5 billion in 2024 to $13.0 billion in 2034 at an 11.1% CAGR, driven by launches and label expansions in the anti-FcRn class (argenx Vyvgart Hytrulo, Johnson & Johnson Imaavy nipocalimab), complement inhibitors (Alexion/AstraZeneca Ultomiris, Soliris), and BAFF/BLyS-targeting therapies (Cytokinetics aficamten in adjacent indications). The forecast supports the ongoing peptide-therapeutic case in autoimmune indications where synthetic peptide-vaccine and peptide-immunomodulator approaches (thymalfasin, thymosin analogs) are being evaluated as adjuncts to the biologics-first standard-of-care. Anti-FcRn represents the fastest-growing MG segment given the manageable safety profile and infrequent dosing versus the plasmapheresis and IVIG protocols that dominated the pre-Vyvgart era.